par4 ap Search Results


protease activated receptor 4 par4  (Proteintech)
92
Proteintech protease activated receptor 4 par4
Protease Activated Receptor 4 Par4, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par4+ap/pmc11255362__BLOODA_ADV___2023___012308___mmc4-14-22-38?v=Proteintech
Average 92 stars, based on 1 article reviews
protease activated receptor 4 par4 - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier
pawr  (Proteintech)
90
Proteintech pawr
Pawr, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par4+ap/pm41862993-179-8-9?v=Proteintech
Average 90 stars, based on 1 article reviews
pawr - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
par4 agonist peptide aypgkf-nh 2  (GenScript corporation)
90
GenScript corporation par4 agonist peptide aypgkf-nh 2
RAG8 treatment impairs PAR (protease-activated receptor) 4–mediated platelet activation. A , SR-B1 (scavenger receptor class B type I)/LDLR (low-density lipoprotein receptor) double knockout (DKO) mice fed the high-fat, high-cholesterol diet containing cholate (HFCC) for 20 days and treated with the RAG8 or the inactive control SRQ8 pepducins were anesthetized, and their tails were transected across the vein ≈0.5 cm from the tip and placed in a cuvette with warm saline. The time to cessation of bleeding was monitored. Each data point represents an individual mouse (n=12, 14). B and C , SR-B1/LDLR DKO mice were fed the HFCC for 14 days and treated with the RAG8 or the inactive control SRQ8 pepducins (n=4 each). Platelets were prepared from blood collected retro-orbitally from anesthetized mice. Platelet activation was measured by treatment of platelets with either thrombin or a synthetic <t>PAR4-AP</t> (PAR4 agonist peptide) by flow cytometry after immunostaining with either ( B ) a FITC (fluorescein isothiocyanate)-labeled Wug-E9 antibody (for P-selectin) or ( C ) a PE (phycoerythrin)-labeled JON/A antibody for active GP IIb/IIIa (glycoprotein). Resting platelet activation levels do not differ between control SRQ8- and RAG8-treated SR-B1/LDLR DKO mice. Units are expressed as median fluorescence intensity (MFI). Bars represent means, and error bars represent SEMs. Data in A passed the normality test and were analyzed by Student t test. Data in B and C were analyzed by 2-way ANOVA with Sidak multiple comparisons post hoc test. **** P <0.0001.
Par4 Agonist Peptide Aypgkf Nh 2, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par4+ap/pmc10597419-42-31-40?v=GenScript+corporation
Average 90 stars, based on 1 article reviews
par4 agonist peptide aypgkf-nh 2 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
par4-ap (aypgkf)  (GL Biochem)
90
GL Biochem par4-ap (aypgkf)
RAG8 treatment impairs PAR (protease-activated receptor) 4–mediated platelet activation. A , SR-B1 (scavenger receptor class B type I)/LDLR (low-density lipoprotein receptor) double knockout (DKO) mice fed the high-fat, high-cholesterol diet containing cholate (HFCC) for 20 days and treated with the RAG8 or the inactive control SRQ8 pepducins were anesthetized, and their tails were transected across the vein ≈0.5 cm from the tip and placed in a cuvette with warm saline. The time to cessation of bleeding was monitored. Each data point represents an individual mouse (n=12, 14). B and C , SR-B1/LDLR DKO mice were fed the HFCC for 14 days and treated with the RAG8 or the inactive control SRQ8 pepducins (n=4 each). Platelets were prepared from blood collected retro-orbitally from anesthetized mice. Platelet activation was measured by treatment of platelets with either thrombin or a synthetic <t>PAR4-AP</t> (PAR4 agonist peptide) by flow cytometry after immunostaining with either ( B ) a FITC (fluorescein isothiocyanate)-labeled Wug-E9 antibody (for P-selectin) or ( C ) a PE (phycoerythrin)-labeled JON/A antibody for active GP IIb/IIIa (glycoprotein). Resting platelet activation levels do not differ between control SRQ8- and RAG8-treated SR-B1/LDLR DKO mice. Units are expressed as median fluorescence intensity (MFI). Bars represent means, and error bars represent SEMs. Data in A passed the normality test and were analyzed by Student t test. Data in B and C were analyzed by 2-way ANOVA with Sidak multiple comparisons post hoc test. **** P <0.0001.
Par4 Ap (Aypgkf), supplied by GL Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par4+ap/pmc04165026-33-7-12?v=GL+Biochem
Average 90 stars, based on 1 article reviews
par4-ap (aypgkf) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
par-4-ap (aypgqv-amide)  (BIOSYNTAN gmbh)
90
BIOSYNTAN gmbh par-4-ap (aypgqv-amide)
RAG8 treatment impairs PAR (protease-activated receptor) 4–mediated platelet activation. A , SR-B1 (scavenger receptor class B type I)/LDLR (low-density lipoprotein receptor) double knockout (DKO) mice fed the high-fat, high-cholesterol diet containing cholate (HFCC) for 20 days and treated with the RAG8 or the inactive control SRQ8 pepducins were anesthetized, and their tails were transected across the vein ≈0.5 cm from the tip and placed in a cuvette with warm saline. The time to cessation of bleeding was monitored. Each data point represents an individual mouse (n=12, 14). B and C , SR-B1/LDLR DKO mice were fed the HFCC for 14 days and treated with the RAG8 or the inactive control SRQ8 pepducins (n=4 each). Platelets were prepared from blood collected retro-orbitally from anesthetized mice. Platelet activation was measured by treatment of platelets with either thrombin or a synthetic <t>PAR4-AP</t> (PAR4 agonist peptide) by flow cytometry after immunostaining with either ( B ) a FITC (fluorescein isothiocyanate)-labeled Wug-E9 antibody (for P-selectin) or ( C ) a PE (phycoerythrin)-labeled JON/A antibody for active GP IIb/IIIa (glycoprotein). Resting platelet activation levels do not differ between control SRQ8- and RAG8-treated SR-B1/LDLR DKO mice. Units are expressed as median fluorescence intensity (MFI). Bars represent means, and error bars represent SEMs. Data in A passed the normality test and were analyzed by Student t test. Data in B and C were analyzed by 2-way ANOVA with Sidak multiple comparisons post hoc test. **** P <0.0001.
Par 4 Ap (Aypgqv Amide), supplied by BIOSYNTAN gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par4+ap/10__1189_slash_jlb__3ab1013___567r-38-3-8?v=BIOSYNTAN+gmbh
Average 90 stars, based on 1 article reviews
par-4-ap (aypgqv-amide) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
par4-ap (gypgkfc)  (Sawady Technology Co Ltd)
90
Sawady Technology Co Ltd par4-ap (gypgkfc)
RAG8 treatment impairs PAR (protease-activated receptor) 4–mediated platelet activation. A , SR-B1 (scavenger receptor class B type I)/LDLR (low-density lipoprotein receptor) double knockout (DKO) mice fed the high-fat, high-cholesterol diet containing cholate (HFCC) for 20 days and treated with the RAG8 or the inactive control SRQ8 pepducins were anesthetized, and their tails were transected across the vein ≈0.5 cm from the tip and placed in a cuvette with warm saline. The time to cessation of bleeding was monitored. Each data point represents an individual mouse (n=12, 14). B and C , SR-B1/LDLR DKO mice were fed the HFCC for 14 days and treated with the RAG8 or the inactive control SRQ8 pepducins (n=4 each). Platelets were prepared from blood collected retro-orbitally from anesthetized mice. Platelet activation was measured by treatment of platelets with either thrombin or a synthetic <t>PAR4-AP</t> (PAR4 agonist peptide) by flow cytometry after immunostaining with either ( B ) a FITC (fluorescein isothiocyanate)-labeled Wug-E9 antibody (for P-selectin) or ( C ) a PE (phycoerythrin)-labeled JON/A antibody for active GP IIb/IIIa (glycoprotein). Resting platelet activation levels do not differ between control SRQ8- and RAG8-treated SR-B1/LDLR DKO mice. Units are expressed as median fluorescence intensity (MFI). Bars represent means, and error bars represent SEMs. Data in A passed the normality test and were analyzed by Student t test. Data in B and C were analyzed by 2-way ANOVA with Sidak multiple comparisons post hoc test. **** P <0.0001.
Par4 Ap (Gypgkfc), supplied by Sawady Technology Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par4+ap/pmc01572489-90-3-20?v=Sawady+Technology+Co+Ltd
Average 90 stars, based on 1 article reviews
par4-ap (gypgkfc) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
par-4-ap  (GenBiotech)
90
GenBiotech par-4-ap
RAG8 treatment impairs PAR (protease-activated receptor) 4–mediated platelet activation. A , SR-B1 (scavenger receptor class B type I)/LDLR (low-density lipoprotein receptor) double knockout (DKO) mice fed the high-fat, high-cholesterol diet containing cholate (HFCC) for 20 days and treated with the RAG8 or the inactive control SRQ8 pepducins were anesthetized, and their tails were transected across the vein ≈0.5 cm from the tip and placed in a cuvette with warm saline. The time to cessation of bleeding was monitored. Each data point represents an individual mouse (n=12, 14). B and C , SR-B1/LDLR DKO mice were fed the HFCC for 14 days and treated with the RAG8 or the inactive control SRQ8 pepducins (n=4 each). Platelets were prepared from blood collected retro-orbitally from anesthetized mice. Platelet activation was measured by treatment of platelets with either thrombin or a synthetic <t>PAR4-AP</t> (PAR4 agonist peptide) by flow cytometry after immunostaining with either ( B ) a FITC (fluorescein isothiocyanate)-labeled Wug-E9 antibody (for P-selectin) or ( C ) a PE (phycoerythrin)-labeled JON/A antibody for active GP IIb/IIIa (glycoprotein). Resting platelet activation levels do not differ between control SRQ8- and RAG8-treated SR-B1/LDLR DKO mice. Units are expressed as median fluorescence intensity (MFI). Bars represent means, and error bars represent SEMs. Data in A passed the normality test and were analyzed by Student t test. Data in B and C were analyzed by 2-way ANOVA with Sidak multiple comparisons post hoc test. **** P <0.0001.
Par 4 Ap, supplied by GenBiotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par4+ap/pm26082997-32-26-28?v=GenBiotech
Average 90 stars, based on 1 article reviews
par-4-ap - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
par-4 agonist aypgkf  (Verum Diagnostica GmbH)
90
Verum Diagnostica GmbH par-4 agonist aypgkf
RAG8 treatment impairs PAR (protease-activated receptor) 4–mediated platelet activation. A , SR-B1 (scavenger receptor class B type I)/LDLR (low-density lipoprotein receptor) double knockout (DKO) mice fed the high-fat, high-cholesterol diet containing cholate (HFCC) for 20 days and treated with the RAG8 or the inactive control SRQ8 pepducins were anesthetized, and their tails were transected across the vein ≈0.5 cm from the tip and placed in a cuvette with warm saline. The time to cessation of bleeding was monitored. Each data point represents an individual mouse (n=12, 14). B and C , SR-B1/LDLR DKO mice were fed the HFCC for 14 days and treated with the RAG8 or the inactive control SRQ8 pepducins (n=4 each). Platelets were prepared from blood collected retro-orbitally from anesthetized mice. Platelet activation was measured by treatment of platelets with either thrombin or a synthetic <t>PAR4-AP</t> (PAR4 agonist peptide) by flow cytometry after immunostaining with either ( B ) a FITC (fluorescein isothiocyanate)-labeled Wug-E9 antibody (for P-selectin) or ( C ) a PE (phycoerythrin)-labeled JON/A antibody for active GP IIb/IIIa (glycoprotein). Resting platelet activation levels do not differ between control SRQ8- and RAG8-treated SR-B1/LDLR DKO mice. Units are expressed as median fluorescence intensity (MFI). Bars represent means, and error bars represent SEMs. Data in A passed the normality test and were analyzed by Student t test. Data in B and C were analyzed by 2-way ANOVA with Sidak multiple comparisons post hoc test. **** P <0.0001.
Par 4 Agonist Aypgkf, supplied by Verum Diagnostica GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par4+ap/pmc06522348-119-48-55?v=Verum+Diagnostica+GmbH
Average 90 stars, based on 1 article reviews
par-4 agonist aypgkf - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
par-4-ap  (Innovagen AB)
90
Innovagen AB par-4-ap
RAG8 treatment impairs PAR (protease-activated receptor) 4–mediated platelet activation. A , SR-B1 (scavenger receptor class B type I)/LDLR (low-density lipoprotein receptor) double knockout (DKO) mice fed the high-fat, high-cholesterol diet containing cholate (HFCC) for 20 days and treated with the RAG8 or the inactive control SRQ8 pepducins were anesthetized, and their tails were transected across the vein ≈0.5 cm from the tip and placed in a cuvette with warm saline. The time to cessation of bleeding was monitored. Each data point represents an individual mouse (n=12, 14). B and C , SR-B1/LDLR DKO mice were fed the HFCC for 14 days and treated with the RAG8 or the inactive control SRQ8 pepducins (n=4 each). Platelets were prepared from blood collected retro-orbitally from anesthetized mice. Platelet activation was measured by treatment of platelets with either thrombin or a synthetic <t>PAR4-AP</t> (PAR4 agonist peptide) by flow cytometry after immunostaining with either ( B ) a FITC (fluorescein isothiocyanate)-labeled Wug-E9 antibody (for P-selectin) or ( C ) a PE (phycoerythrin)-labeled JON/A antibody for active GP IIb/IIIa (glycoprotein). Resting platelet activation levels do not differ between control SRQ8- and RAG8-treated SR-B1/LDLR DKO mice. Units are expressed as median fluorescence intensity (MFI). Bars represent means, and error bars represent SEMs. Data in A passed the normality test and were analyzed by Student t test. Data in B and C were analyzed by 2-way ANOVA with Sidak multiple comparisons post hoc test. **** P <0.0001.
Par 4 Ap, supplied by Innovagen AB, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par4+ap/pm12632026-48-7-11?v=Innovagen+AB
Average 90 stars, based on 1 article reviews
par-4-ap - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


RAG8 treatment impairs PAR (protease-activated receptor) 4–mediated platelet activation. A , SR-B1 (scavenger receptor class B type I)/LDLR (low-density lipoprotein receptor) double knockout (DKO) mice fed the high-fat, high-cholesterol diet containing cholate (HFCC) for 20 days and treated with the RAG8 or the inactive control SRQ8 pepducins were anesthetized, and their tails were transected across the vein ≈0.5 cm from the tip and placed in a cuvette with warm saline. The time to cessation of bleeding was monitored. Each data point represents an individual mouse (n=12, 14). B and C , SR-B1/LDLR DKO mice were fed the HFCC for 14 days and treated with the RAG8 or the inactive control SRQ8 pepducins (n=4 each). Platelets were prepared from blood collected retro-orbitally from anesthetized mice. Platelet activation was measured by treatment of platelets with either thrombin or a synthetic PAR4-AP (PAR4 agonist peptide) by flow cytometry after immunostaining with either ( B ) a FITC (fluorescein isothiocyanate)-labeled Wug-E9 antibody (for P-selectin) or ( C ) a PE (phycoerythrin)-labeled JON/A antibody for active GP IIb/IIIa (glycoprotein). Resting platelet activation levels do not differ between control SRQ8- and RAG8-treated SR-B1/LDLR DKO mice. Units are expressed as median fluorescence intensity (MFI). Bars represent means, and error bars represent SEMs. Data in A passed the normality test and were analyzed by Student t test. Data in B and C were analyzed by 2-way ANOVA with Sidak multiple comparisons post hoc test. **** P <0.0001.

Journal: Arteriosclerosis, Thrombosis, and Vascular Biology

Article Title: PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice

doi: 10.1161/ATVBAHA.123.319767

Figure Lengend Snippet: RAG8 treatment impairs PAR (protease-activated receptor) 4–mediated platelet activation. A , SR-B1 (scavenger receptor class B type I)/LDLR (low-density lipoprotein receptor) double knockout (DKO) mice fed the high-fat, high-cholesterol diet containing cholate (HFCC) for 20 days and treated with the RAG8 or the inactive control SRQ8 pepducins were anesthetized, and their tails were transected across the vein ≈0.5 cm from the tip and placed in a cuvette with warm saline. The time to cessation of bleeding was monitored. Each data point represents an individual mouse (n=12, 14). B and C , SR-B1/LDLR DKO mice were fed the HFCC for 14 days and treated with the RAG8 or the inactive control SRQ8 pepducins (n=4 each). Platelets were prepared from blood collected retro-orbitally from anesthetized mice. Platelet activation was measured by treatment of platelets with either thrombin or a synthetic PAR4-AP (PAR4 agonist peptide) by flow cytometry after immunostaining with either ( B ) a FITC (fluorescein isothiocyanate)-labeled Wug-E9 antibody (for P-selectin) or ( C ) a PE (phycoerythrin)-labeled JON/A antibody for active GP IIb/IIIa (glycoprotein). Resting platelet activation levels do not differ between control SRQ8- and RAG8-treated SR-B1/LDLR DKO mice. Units are expressed as median fluorescence intensity (MFI). Bars represent means, and error bars represent SEMs. Data in A passed the normality test and were analyzed by Student t test. Data in B and C were analyzed by 2-way ANOVA with Sidak multiple comparisons post hoc test. **** P <0.0001.

Article Snippet: For pepducin-treated mouse groups, platelets (1×10 6 washed mouse platelets per reaction) were resting or activated with 1 U/mL α-thrombin (HT 1002A; Enzyme Research Laboratories, South Bend, IN) or 300 μM PAR4 agonist peptide (AYPGKF-NH 2 ; custom synthesized by Genscript, Piscataway, NJ) in the presence of 2 mM CaCl 2 .

Techniques: Activation Assay, Double Knockout, Control, Saline, Flow Cytometry, Immunostaining, Labeling, Fluorescence